Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14973162 | 0.90 | MEN1 (0.46) | PTGS2MEN1KMT2ACA12CA1 | |
| SCHEMBL14973349 | 0.87 | MAPT (0.44) | PTGS2TLR7KAT6ASCN10AMAPT | |
| SCHEMBL14973000 | 0.84 | MRGPRX4 (0.45) | PTGS2TLR7KAT6ASCN10ACA12 | |
| SCHEMBL14973309 | 0.79 | MAPT (0.43) | ALDH1A1MAPT | |
| SCHEMBL14973345 | 0.76 | CA12 (0.46) | PTGS2TLR7CA12CA1CA2 | |
| SCHEMBL14973138 | 0.75 | SIRT2 (0.37) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL14937463 | 0.75 | CA9 (0.41) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL14973107 | 0.74 | KDM4E (0.43) | KMT2AALDH1A1MAPT | |
| SCHEMBL14973305 | 0.74 | TRPV1 (0.37) | PTGS2CA12CA1CA2CA9 | |
| SCHEMBL14973167 | 0.73 | ADAMTS4 (0.42) | PTGS2TLR7CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877944-B2 | 3-oxo-2,3-dihydro-1H-isoindole-4-carboxamides as PARP inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-11-04 | — | — | US | disclosed |
| EP-2604602-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-20130137865-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137865-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | GRIN2C, GRIN2B, GRIN3A | PTGS2 1113/4885TLR7 2734/4885KAT6A 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.